الفهرس | Only 14 pages are availabe for public view |
Abstract The main goal of this work is to employ nanoparticles technology in the form of cubosomes to enhance the oral bioavailability of BCS class II drug, clopidogrel bisulphate (CB) by enhancing its solubility in intestinal pH, which is its main site of absorption and its formulation into convenient, stable dosage form suitable for patient use. CB is a thienopyridene class anti-platelet oral drug. It is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease |